You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 287 No. 1, January 2, 2002 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communication
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (27)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Statistics and Research Methods
 •Conflict of Interest
 •Alert me on articles by topic

Medical Innovation and Institutional Interdependence

Rethinking University-Industry Connections

Annetine C. Gelijns, PhD; Samuel O. Thier, MD

JAMA. 2002;287:72-77.

University-industry research collaborations have been key to a continued high degree of technological innovation in medicine. Recently, however, critical questions have been posed about the potential negative aspects of highly productive means of encouraging innovation. Concerns center on blurring roles between academic research and the commercial world and the implications of universities' newfound readiness to benefit financially from their intellectual property. The roles of both parties are often inadequately captured by considering members of university faculties as single-mindedly devoted to the advancement of fundamental knowledge and industrial firms as mere developers of university research. Rather, medical innovation depends on extensive interactions between universities and industry, with knowledge and technology transfer flowing in both directions. These interactions have had important public health and economic benefits. Yet, there is a risk to the university-industry relationship if the cultural and ethical principles of one partner overwhelm those of the other. Therefore, universities and industry need to maximize the upsides of collaboration and minimize the downsides by means of internal organizational change as well as formation of new models of collaboration, such as intellectual partnerships or virtual research organizations. This article reviews the numerous institutional patterns of innovation and draws implications for organizational and public policies.


Author Affiliations: International Center for Health Outcomes and Innovation Research (INCHOIR), College of Physicians and Surgeons and School of Public Health, Columbia University, New York, NY (Dr Gelijns); and Partners Health Care System and Harvard Medical School, Boston, Mass (Dr Thier).


RELATED LETTER

Partnerships Between Universities and Industry
Lynn H. Ehrle, Philip Lempert, Samuel O. Thier, and Annetine C. Gelijns
JAMA. 2002;287(11):1398-1400.
EXTRACT | FULL TEXT  

RELATED ARTICLES

January 2, 2002
JAMA. 2002;287(1):129-130.
EXTRACT | FULL TEXT  

Managing Conflicts of Interest in the Conduct of Clinical Trials
Karine Morin, Herbert Rakatansky, Frank A. Riddick, Jr, Leonard J. Morse, John M. O'Bannon III, Michael S. Goldrich, Priscilla Ray, Matthew Weiss, Robert M. Sade, and Monique A. Spillman
JAMA. 2002;287(1):78-84.
ABSTRACT | FULL TEXT  

Legal Issues in Scientific Research
Paul E. Kalb and Kristin Graham Koehler
JAMA. 2002;287(1):85-91.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Making progress in psychosocial research in dementia
Iliffe et al.
Dementia 2008;7:167-174.
ABSTRACT  

The Contract Research Organization and the Commercialization of Scientific Research
Mirowski and Van Horn
Social Studies of Science 2005;35:503-548.
ABSTRACT  

Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry
Mello et al.
NEJM 2005;352:2202-2210.
ABSTRACT | FULL TEXT  

University-Based Science and Biotechnology Products: Defining the Boundaries of Intellectual Property
Kesselheim and Avorn
JAMA 2005;293:850-854.
ABSTRACT | FULL TEXT  

Ethical Concerns in Industry Support of Continuing Medical Education: The Con Side
Packer and Parke
Arch Ophthalmol 2004;122:773-776.
FULL TEXT  

The Moral Economy of the Drug Company-Medical Scientist Collaboration in Interwar America
Rasmussen
Social Studies of Science 2004;34:161-185.
ABSTRACT  

United Kingdom research governance strategy
Kerrison et al.
BMJ 2003;327:553-556.
FULL TEXT  

Industry Funding of Clinical Trials: Benefit or Bias?
Chopra
JAMA 2003;290:113-114.
FULL TEXT  

Central Challenges Facing the National Clinical Research Enterprise
Sung et al.
JAMA 2003;289:1278-1287.
ABSTRACT | FULL TEXT  

Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman et al.
JAMA 2003;289:454-465.
ABSTRACT | FULL TEXT  

A Central Institutional Review Board for Multi-Institutional Trials
Christian et al.
NEJM 2002;346:1405-1408.
FULL TEXT  

Partnerships Between Universities and Industry
Ehrle et al.
JAMA 2002;287:1398-1400.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.